150 related articles for article (PubMed ID: 25784388)
1. Dose selection of siltuximab for multicentric Castleman's disease.
Mayer CL; Xie L; Bandekar R; Qi M; van de Velde H; Reddy M; Qin X; Davis HM; Puchalski TA
Cancer Chemother Pharmacol; 2015 May; 75(5):1037-45. PubMed ID: 25784388
[TBL] [Abstract][Full Text] [Related]
2. Siltuximab: a new option for the management of Castleman's disease.
Barquero N
Drugs Today (Barc); 2015 Jan; 51(1):21-8. PubMed ID: 25685858
[TBL] [Abstract][Full Text] [Related]
3. Analysis of Inflammatory and Anemia-Related Biomarkers in a Randomized, Double-Blind, Placebo-Controlled Study of Siltuximab (Anti-IL6 Monoclonal Antibody) in Patients With Multicentric Castleman Disease.
Casper C; Chaturvedi S; Munshi N; Wong R; Qi M; Schaffer M; Bandekar R; Hall B; van de Velde H; Vermeulen J; Reddy M; van Rhee F
Clin Cancer Res; 2015 Oct; 21(19):4294-304. PubMed ID: 26124203
[TBL] [Abstract][Full Text] [Related]
4. Siltuximab: A Review in Idiopathic (Human Herpesvirus-8-Negative) Multicentric Castleman Disease.
Lyseng-Williamson KA
BioDrugs; 2015 Dec; 29(6):399-406. PubMed ID: 26394632
[TBL] [Abstract][Full Text] [Related]
5. Siltuximab for multicentric Castleman disease.
Liu YC; Stone K; van Rhee F
Expert Rev Hematol; 2014 Oct; 7(5):545-57. PubMed ID: 25110138
[TBL] [Abstract][Full Text] [Related]
6. Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial.
van Rhee F; Wong RS; Munshi N; Rossi JF; Ke XY; Fosså A; Simpson D; Capra M; Liu T; Hsieh RK; Goh YT; Zhu J; Cho SG; Ren H; Cavet J; Bandekar R; Rothman M; Puchalski TA; Reddy M; van de Velde H; Vermeulen J; Casper C
Lancet Oncol; 2014 Aug; 15(9):966-74. PubMed ID: 25042199
[TBL] [Abstract][Full Text] [Related]
7. Siltuximab (Sylvant) for treatment of multicentric castleman's disease.
Med Lett Drugs Ther; 2015 Jan; 57(1459):e8. PubMed ID: 25555075
[No Abstract] [Full Text] [Related]
8. Mechanistic pharmacokinetic/target engagement/pharmacodynamic (PK/TE/PD) modeling in deciphering interplay between a monoclonal antibody and its soluble target in cynomolgus monkeys.
Wang W; Wang X; Doddareddy R; Fink D; McIntosh T; Davis HM; Zhou H
AAPS J; 2014 Jan; 16(1):129-39. PubMed ID: 24287601
[TBL] [Abstract][Full Text] [Related]
9. A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease.
Kurzrock R; Voorhees PM; Casper C; Furman RR; Fayad L; Lonial S; Borghaei H; Jagannath S; Sokol L; Usmani SZ; van de Velde H; Qin X; Puchalski TA; Hall B; Reddy M; Qi M; van Rhee F
Clin Cancer Res; 2013 Jul; 19(13):3659-70. PubMed ID: 23659971
[TBL] [Abstract][Full Text] [Related]
10. A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease.
van Rhee F; Casper C; Voorhees PM; Fayad LE; van de Velde H; Vermeulen J; Qin X; Qi M; Tromp B; Kurzrock R
Oncotarget; 2015 Oct; 6(30):30408-19. PubMed ID: 26327301
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic and pharmacodynamic modeling of an anti-interleukin-6 chimeric monoclonal antibody (siltuximab) in patients with metastatic renal cell carcinoma.
Puchalski T; Prabhakar U; Jiao Q; Berns B; Davis HM
Clin Cancer Res; 2010 Mar; 16(5):1652-61. PubMed ID: 20179212
[TBL] [Abstract][Full Text] [Related]
12. Population pharmacokinetics of siltuximab: impact of disease state.
Nikanjam M; Yang J; Capparelli EV
Cancer Chemother Pharmacol; 2019 Nov; 84(5):993-1001. PubMed ID: 31482226
[TBL] [Abstract][Full Text] [Related]
13. Siltuximab and hematologic malignancies. A focus in non Hodgkin lymphoma.
Ferrario A; Merli M; Basilico C; Maffioli M; Passamonti F
Expert Opin Investig Drugs; 2017 Mar; 26(3):367-373. PubMed ID: 28140696
[TBL] [Abstract][Full Text] [Related]
14. A phase 1, randomized study to assess the pharmacokinetic comparability of siltuximab derived from two different cell lines in healthy subjects.
Xu C; Han C; Marini J; Ford J; Marciniak S; Lopez M; Frederick B; de Vries D; Bandekar R; Davis HM; Zhou H; Puchalski TA
Clin Pharmacol Drug Dev; 2014 Jul; 3(4):328-34. PubMed ID: 27128840
[TBL] [Abstract][Full Text] [Related]
15. Deriving health utility values from a randomized, double-blind, placebo-controlled trial of siltuximab in subjects with multicentric Castleman's disease.
Vernon M; Robinson D; Trundell D; Ishak J; Jen MH; Brazier J
Curr Med Res Opin; 2016 Jul; 32(7):1193-200. PubMed ID: 26972925
[TBL] [Abstract][Full Text] [Related]
16. Clinical development of siltuximab.
Davis CC; Shah KS; Lechowicz MJ
Curr Oncol Rep; 2015 Jul; 17(7):29. PubMed ID: 25986720
[TBL] [Abstract][Full Text] [Related]
17. Therapy of Castleman's disease with siltuximab - case report and review of literature.
Adam Z; Zeman D; Chodacki A; Pour L; Horváth T; Benda P; Adamová Z; Krejčí M; Tomíška M; Boichuk I; Král Z
Klin Onkol; 2023; 37(4):320-329. PubMed ID: 38195387
[TBL] [Abstract][Full Text] [Related]
18. Impact of siltuximab on patient-related outcomes in multicentric Castleman's disease.
Sitenga J; Aird G; Ahmed A; Silberstein PT
Patient Relat Outcome Meas; 2018; 9():35-41. PubMed ID: 29391839
[TBL] [Abstract][Full Text] [Related]
19. Siltuximab (Sylvant). Castleman's disease: good symptomatic efficacy in some patients.
Prescrire Int; 2016 Mar; 25(169):61-4. PubMed ID: 27152394
[TBL] [Abstract][Full Text] [Related]
20. FDA approval: siltuximab for the treatment of patients with multicentric Castleman disease.
Deisseroth A; Ko CW; Nie L; Zirkelbach JF; Zhao L; Bullock J; Mehrotra N; Del Valle P; Saber H; Sheth C; Gehrke B; Justice R; Farrell A; Pazdur R
Clin Cancer Res; 2015 Mar; 21(5):950-4. PubMed ID: 25601959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]